GC Labcell Secures Patent for Gene Drug Delivery Composition for Brain Disease Treatment

[Asia Economy, reporter Jo Hyun] GC Labcell announced on July 21 that it has obtained a patent from the Korean Intellectual Property Office for a composition related to gene drug delivery for the treatment of brain diseases.

This patent covers a recombinant protein with a specific structure that enables efficient delivery of therapeutic drugs to the brain's nervous system via intranasal administration, as well as gene composition technology utilizing this protein.

For the treatment of brain diseases, it is crucial to effectively deliver drugs to the brain's nervous system. However, conventional drug administration methods have limitations because drugs cannot cross the blood-brain barrier, resulting in limited symptom improvement and side effects caused by administering large amounts of drugs.

GC Labcell confirmed the efficacy of this technology through animal testing. The company explained that when a gene therapy composition was injected into an animal model of GM1 gangliosidosis, a rare pediatric neurodegenerative disease, a high level of gene expression was observed in brain tissue.

Hwang Yukyung, head of the Cell Therapy Research Institute at GC Labcell, stated, "As we have secured a fundamental technology that can be applied to a wide range of brain and nervous system diseases, we will accelerate the development of next-generation gene therapies."

This content was produced with the assistance of AI translation services.